Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-07-10
2007-07-10
Haddad, Maher M. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388240
Reexamination Certificate
active
10489866
ABSTRACT:
A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus, a method of treating autoimmune diseases, rheumatism or rheumatoid arthritis is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of diagnosing rheumatism too.
REFERENCES:
patent: 6632927 (2003-10-01), Adair et al.
patent: 2002/0188962 (2002-12-01), Denhardt et al.
patent: 2004/0234524 (2004-11-01), Uede et al.
patent: 2006/0002923 (2006-01-01), Uede et al.
patent: 0 125 023 (1984-11-01), None
patent: 239 400 (1987-09-01), None
patent: 0705 842 (1996-04-01), None
patent: 0 921 189 (1998-11-01), None
patent: 1 408 113 (2004-04-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 94/20632 (1994-09-01), None
patent: WO 95/28426 (1995-10-01), None
patent: WO 98/07750 (1998-02-01), None
patent: WO 98/08379 (1998-03-01), None
patent: WO 98/56405 (1998-12-01), None
patent: WO 99/08730 (1999-02-01), None
patent: 00 63247 (2000-10-01), None
patent: WO 00/63241 (2000-10-01), None
patent: 01/71358 (2001-09-01), None
patent: W 02/32940 (2002-04-01), None
patent: WO 03/046135 (2003-06-01), None
Rudikoff et al Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Panka et al. Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. Proc Natl Acad Sci U S A. 85(9):3080-3084, 1988.
Bautista et al Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem. Sep. 16, 1994;269(37):23280-5.
Shigeyuki Kon, et al., “Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences”, Journal of Cellular Biochemistry, vol. 84, No. 2, pp. 420-432 2002.
Peter T. Jones, et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse”, NATURE, vol. 321, pp. 522-525 May 29, 1986.
Diosdado S. Bautista, et al., “Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin”, The Journal of Biological Chemistry, vol. 269, No. 37, pp. 23280-23285 Sep. 16, 1994.
Yoshiki Saitoh, et al., Laboratory Investigation, vol. 72, No. 1, pp. 55-63 1995.
Yasuyuki Yokosaki, et al., The Journal of Biological Chemistry, vol. 274, No. 51, pp. 36328-36334 Dec. 17, 1999.
Philip M. Greeen, et al., FEBS Letters, vol. 503, pp. 75-79 2001.
J. R. Waller, et al., British Journal of Surgery, vol. 88, pp. 1429-1441 2001.
Satu R. K. Lehtonen, et al., Transplantation, vol. 72, No. 6, pp. 1138-1144 Sep. 27, 2001.
Anthony O'Regan, et al., Int.J.Exp. Path, vol. 81, pp. 373-390 2000.
Kayla J. Bayless, et al., The Journal of Biological Chemistry, vol. 276, No. 16, pp. 13483-13489 Apr. 20, 2001.
Yasuyuki Taooka, et al., The Journal of Cell Biology, vol. 145, No. 2, pp. 413-420 Apr. 19, 1999.
Inhibitory Effects of MLDG-containing Heterodimeric Disintegrins Reveal Distinct Structural Requirements for Interaction of the Integrin α9β1 with VCAM-1, Tenascin-C, and Osteopontin, Cesary marcinkiewics, et al. , The Journal of Biological Chem., Oct. 13, 2000, vol. 275, No. 41, pp. 31930-31937.
Mapping of the Cryptic Integrin-Binding Site in Osteopontin Suggests a New Mechanism by Which Thrombin Can Regulate Inflammation and Tissue Repair, Yasuyuki Yokasaki, et al. Trends Cardiovasc Med. vol. 10, No. 4, 2000 pp. 155-159.
Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival, David T. Denhardts, et al., The Journal of Clinical Investigation, May 2001, vol. 107, No. 9, pp. 1055-1061.
Mice Lacking Osteopontin Show Normal Development and Bone Structure but Display Altered osteoclast Formation In Vitro, Susan R. Rittling, et al. Journal of Bone and Mineral Research, vol. 13, No. 7, 1998, pp. 1101-1111.
Eta-1 (Osteopontin): An Early Component of Type-1 (Cell Mediated) Immunity, Samy Ashkar, et al. Science, Feb. 4, 2000, vol. 287, pp. 860-364.
Antibodies to Different Peptides in Osteopontin Reveal Complexities in the Various Secreted Forms, Shigeyuki Kon, et al. Journal of Cellular Biochemistry , 2000, 77, pp. 487-498.
Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice, Kenji Yamoto, et al. PNAS, vol. 99, No. 7, pp. 4556-4561.
Enhanced Local Production of Osteopontin in Rheumatoid Joints, Shiro Ohshima, et al., The Journal of Rheumatogoty 2002, vol. 29, No. 10, pp. 2061-2067.
The Third Annual Meeting of Osteopontin Study Group, May 27, 2000 (with English translation of related sections).
The Fourth Annual Meeting of Osteopontin Study Group, Jun. 9, 2001 (with English translations of related sections).
Analysis of the α4β Integrin-Osteopontin Interaction, Simon T. Barry, et al., Experimental Cell Research, 2000, 258, pp. 342-351.
Chromic Allograft Nephropathy—Biopsy Findings and Outcome, Poul Freese, et al., Nephrol Dial Transplant, 2001, 16, pp. 2001-2406.
Samy Ashkar, et al., “Eta-1 (Osteopontin): An Early Component of Type-1 (Cell-Mediated) Immunity”, Science, vol. 287, Feb. 4, 2000, pp. 860-864.
Dorothee Chabas, et al., “The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease”, Science, vol. 294, Nov. 23, 2001, pp. 1731-1735.
Marianne Jansson, et al., “Cutting Edge: Attenuated Experimental Autoimmune Encephalomyelitis in Eta-1/Osteopontin-Deficient Mice1”, The American Association of Immunologists, 2002, pp. 2096-2099.
Mukundan G. Attur, et al., “Osteopontin an Intrinsic Inhibitor of Inflammation in Cartilage”, Regulation of NO and PGE2by Osteopontin, pp. 578-584.
Butista, D.S. et al. “A Monoclonal Antibody against Osteopontin Inhibitis RGD-Mediated Cell Adhesion to Osteopontin”, Annals of the New York Academy of Sciences, vol. 760, pp. 309-311, XP009033073 1995.
Hotta, Hiroshi et al. “Detection of Various Epitopes of Murine Osteopontin by Monoclonal Antibodies”, Biochemical and Biophysical Research Communications, vol. 257, pp. 6-11, XP002286858.
Rittling, Susan R. et al. “Detection of Mouse Osteopontin by Western Blotting”, Biochemical and Biophysical Research Communications, vol. 250, pp. 287-292, XP002286859.
Sakata, Masahiro et al. “Autoantibodies to Osteopontin in Patients with Osteoarthritis and Rheumatoid Arthritis”. The Journal of Rheumatology, vol. 28, No. 7, pp. 1492-1495, XP009033062.
Petrow, Peter K. et al. “Expression of Osteopontin Messenger RNA and Protein in Rheumatoid Arthritis”, Arthritis & Rheumatism, vol. 43, No. 7, pp. 1597-1605, XP009033184 2000.
Higuchi Hirofumi
Kon Shigeyuki
Maeda Hiroaki
Nakashima Toshihiro
Tokieda Yoshiyuki
Astellas Pharma Inc.
Haddad Maher M.
Juridical Foundation the Chemo-sero-therapeutic Research Institu
LandOfFree
Recombinant anti-osteopontin antibody and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant anti-osteopontin antibody and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant anti-osteopontin antibody and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3734501